Comparison of CellSearch and Circulating Tumor Cells (CTC)-Biopsy Systems in Detecting Peripheral Blood Circulating Tumor Cells in Patients with Gastric Cancer

Ning, Dawei; Cui, Kai; Liu, Min; Ou, Yang; Wang, Zhendan; Zou, Benkui; Shen, Yangyang; Lu, Xinyang; Li, Sheng; Pang, Li

doi:10.12659/msm.926565

Cited by 14 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, high-quality enhanced CT combined with invasive ultrasound gastroscopy is required for assessment, which increases the patient's radiation risk, economic burden, and physical pain. It has been reported that the number of mesenchymal CTC is closely related to the TNM staging and N staging of gastric cancer [40]. is study used CTC before neoadjuvant as the baseline, showing that baseline interstitial CTC and N staging were significantly correlated (P � 0.034) and positively correlated.…”

Section: Discussionmentioning

confidence: 82%

Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer

Zhu

Luo

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. To explore the application value of circulating tumor cells (CTCs) and circulating free DNA (cfDNA) from peripheral blood in the prognosis of advanced gastric cancer (AGC). Here, we measured CTCs and cfDNA quantity for predicting the outcome of patients. Patients and Methods. Forty-five patients with advanced gastric cancer who underwent neoadjuvant chemotherapy and surgical treatment were enrolled in this study. All patients received neoadjuvant chemotherapy with paclitaxel + S-1 + oxaliplatin (PSOX) regimen, and CTCs and cfDNA of the peripheral blood were detected before and after neoadjuvant therapy. Relationships between the number/type of CTC or cfDNA and the efficacy of neoadjuvant chemotherapy were analyzed. Results. Among 45 patients, 43 (95.6%) were positive, and the positive rate of mesenchymal CTC was increased with the increase in the T stage. The proportion of mesenchymal CTC was positively correlated with the N stage ( P < 0.05 ), and the larger N stage will have the higher proportion of mesenchymal CTC. Patients with a small number of mesenchymal CTC before neoadjuvant chemotherapy were more likely to achieve partial response (PR) with neoadjuvant therapy. Patients with positive CA-199 were more likely to achieve PR with neoadjuvant therapy ( P < 0.05 ). Patients in the PR group were more likely to have decreased/unchanged cfDNA concentration after neoadjuvant therapy ( P = 0.119 ). After neoadjuvant therapy (before surgery), the cfDNA concentration was higher and the efficacy of neoadjuvant therapy (SD or PD) was lower ( P = 0.045 ). Conclusions. Peripheral blood CTC, especially interstitial CTC and cfDNA, has a certain value in predicting the efficacy and prognosis of neoadjuvant chemotherapy in advanced gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 82%

Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer

Zhu

Luo

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Considering the positivity and EMT, our study focused on effective size-based method for CTC studies in ovarian cancer. Among all the physical methods, the ISET filtration technology showed a satisfactory CTC positive rate in gastric cancer (59.32%), non-small cell lung cancer (88%), pancreatic cancer (93%) (37,48,49). Herein, the CTCBIOPSY ® platform based on the ISET technology was first applied in CTC detection in ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Only cells that appear as large cells with deep stained nuclei and/or atypia, which are features of tumor cells under the microscope, were identified as CTCs. The criteria for the confirmation of CTCs are shown in Table S1 (37).…”

Section: Ctc Detection and Characterizationmentioning

confidence: 99%

Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer

Jie¹,

Zhang²,

Du³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Circulating tumor cells (CTCs) have considered to be promising liquid biopsy in cancer due to the intact information of whole cells and the potential to reflect micrometastasis. However, CTCs research are extremely limited in ovarian cancer, probably due to their rarity. The predictive value of CTCs and circulating tumor microemboli (CTM) in metastasis remains to be elucidated in ovarian cancer. This study tried to identify CTCs/CTM in ovarian cancer with considerably positive rate. To preliminarily identify the invasive capacity of CTCs/CTM, the epithelial-mesenchymal transition (EMT) patterns of CTCs/CTM was evaluated. Moreover, for comprehensive understanding of invasiveness of disseminated cells in ovarian cancer, EMT pattern of exfoliated tumor cells in ascites were also confirmed in this study.Methods: Peripheral blood samples and ascites samples were collected from 22 ovarian cancer patients.The Microfiltration combined with morphological analysis was used to detect CTC single cells or cell clusters. Microfiltration combined with morphological analysis was applied in the CTC isolation and identification. EMT was evaluated by immunofluorescence via markers including vimentin and cytokeratin.Results: Microfiltration combined with morphological analysis was introduced to detect CTCs/CTM with a positivity rate of 40.9% in ovarian cancer patients. The number of CTC varied from 1 to 8, with CTM number from 4 to 30. CTCs/CTM of all samples have experienced EMT process. Vimentin was expressed in all CTC samples and all tumor cells in ascites, while cytokeratin was expressed in 44.4% (4/9) of CTC samples. There were no significant differences of the clinical parameters between the CTC-positive and CTC-negative patients.Conclusions: This study showed that both CTCs/CTM and detached tumor cells in ascites might have undergone complete or partial EMT in ovarian cancer. Moreover, microfiltration combined with cytomorphological analysis showed a considerable CTC detection rate.

show abstract

“…Thirdly, different CTC techniques used for detecting the same sample may obtain completely different results; thus, how to choose the most suitable CTC detection method is also a major problem that currently needs to be solved [ 83 , 188 ]. A study aimed to evaluate how two different isolation techniques, evolving the physical (Parsortix®) and biological (MACS®) separation techniques, affect cell morphology.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Detection of circulating tumor cells: opportunities and challenges

Chen

Zhang

et al. 2022

Biomark Res

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are cells that shed from a primary tumor and travel through the bloodstream. Studying the functional and molecular characteristics of CTCs may provide in-depth knowledge regarding highly lethal tumor diseases. Researchers are working to design devices and develop analytical methods that can capture and detect CTCs in whole blood from cancer patients with improved sensitivity and specificity. Techniques using whole blood samples utilize physical prosperity, immunoaffinity or a combination of the above methods and positive and negative enrichment during separation. Further analysis of CTCs is helpful in cancer monitoring, efficacy evaluation and designing of targeted cancer treatment methods. Although many advances have been achieved in the detection and molecular characterization of CTCs, several challenges still exist that limit the current use of this burgeoning diagnostic approach. In this review, a brief summary of the biological characterization of CTCs is presented. We focus on the current existing CTC detection methods and the potential clinical implications and challenges of CTCs. We also put forward our own views regarding the future development direction of CTCs.

show abstract

Comparison of CellSearch and Circulating Tumor Cells (CTC)-Biopsy Systems in Detecting Peripheral Blood Circulating Tumor Cells in Patients with Gastric Cancer

Cited by 14 publications

References 29 publications

Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer

Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer

Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer

Detection of circulating tumor cells: opportunities and challenges

Contact Info

Product

Resources

About